Antithrombotic PreTreatment and Invasive Strategies in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Current antithrombotic treatment for non-ST segment elevation acute coronary syndrome (NSTE-ACS) involves aspirin and P2Y12 inhibitors like ticagrelor or prasugrel.
• The optimal timing for administering ticagrelor in NSTE-ACS patients remains under-investigated.
• Prasugrel use is restricted to patients undergoing percutaneous coronary intervention (PCI) after coronary angiography.

Purpose of the Study:

• To evaluate the optimal timing of ticagrelor administration in NSTE-ACS patients.
• To assess the role of invasive strategy timing based on risk stratification in NSTE-ACS.
• To determine the mortality benefit of early intervention (<24 hours) in high-risk NSTE-ACS patients.

Main Methods:

• Review of current clinical guidelines and landmark trials concerning NSTE-ACS management.
• Analysis of data regarding the efficacy and safety of ticagrelor and prasugrel.
• Stratification of NSTE-ACS patients based on risk scores to guide invasive strategy.

Main Results:

• The optimal timing for ticagrelor initiation in NSTE-ACS is not well-defined.
• Prasugrel is recommended only after coronary angiography and before PCI.
• An early invasive strategy (<24 hours) demonstrates a mortality benefit in selected high-risk NSTE-ACS patients.

Conclusions:

• Further research is needed to establish optimal ticagrelor timing in NSTE-ACS.
• Risk stratification is crucial for guiding the timing of angiography and intervention in NSTE-ACS.
• Early (<24 hours) invasive intervention improves mortality in high-risk NSTE-ACS patients.